Dash Bio Scores $30M Series A
2026-08-05
Tweet
WALTHAM, MA, Dash Bio, the company building the infrastructure that drug development needs for the next generation of medicines, announced it has raised $30 million in Series A financing.
Dash Bio, the company building the infrastructure that drug development needs for the next generation of medicines, announced it has raised $30 million in Series A financing. The round was led by Oak HC/FT, with participation from existing investors, including Freestyle Capital and Swift Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
